Cargando…

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis

Fungisome(®) (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijnant, Gert-Jan, Van Bocxlaer, Katrien, Yardley, Vanessa, Harris, Andy, Alavijeh, Mo, Silva-Pedrosa, Rita, Antunes, Sandra, Mauricio, Isabel, Murdan, Sudaxshina, Croft, Simon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039306/ https://www.ncbi.nlm.nih.gov/pubmed/29673889 http://dx.doi.org/10.1016/j.ijpddr.2018.04.001

Ejemplares similares

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
por: Nath, Proggananda, et al.
Publicado: (2014)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis
por: Riezk, Alaa, et al.
Publicado: (2020)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)
por: Burza, Sakib, et al.
Publicado: (2014)

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2017)

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Cytotoxicity of Amphotericin B and AmBisome: In Silico and In Vivo Evaluation Employing the Chick Embryo Model
por: Khosravi, Ahmad, et al.
Publicado: (2022)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
por: Walker, Louise, et al.
Publicado: (2018)

A Comparison of AmBisome(®) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
por: Jeon, Ga Won, et al.
Publicado: (2007)

Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis
por: Forrester, Sarah, et al.
Publicado: (2019)

AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial( )
por: Burza, Sakib, et al.
Publicado: (2022)

Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome
por: Cencig, Sabrina, et al.
Publicado: (2011)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Hypokalaemia-Induced Rhabdomyolysis after Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL) with High-Dose AmBisome in Bangladesh—A Case Report
por: Marking, Ulrika, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2019)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

AmBisome Induced Avascular Necrosis of the Alae of the Nose of a very young girl suffering from Kala‐azar – a Case Report
por: Maruf, Shomik, et al.
Publicado: (2016)

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2018)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
por: Ponatshego, Ponego Lloyd, et al.
Publicado: (2019)

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2019)

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
Publicado: (2014)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
Publicado: (2014)

Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2023)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
por: Molefi, Mooketsi, et al.
Publicado: (2015)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2019)

Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana In Vitro
por: Riezk, Alaa, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kcg6fej802cfhvufr41jgbrs2e